EnzymeBioSystems S-1/A 25 Jan 18 IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Sep. 30, 2017
Document And Entity Information
Entity Registrant Name	EnzymeBioSystems
Entity Central Index Key	1,471,968
Document Type	S-1/A
Amendment Flag	true
Amendment Description	Amendment No. 1
Document Period End Date	Sep. 30, 2017
Entity Filer Category	Smaller Reporting Company

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Current assets:
Cash and cash equivalents	$ 213,259	$ 41,249	$ 140,042
Prepaid expense	6,000	3,000
Total current assets	219,259	44,249	140,042
TOTAL ASSETS	219,259	44,249	140,042
Current liabilities:
Accounts payable	100	100	100
Accrued expenses	4,000	4,000	4,000
Total current liabilities and total liabilities	4,100	4,100	4,100
Stockholders' equity:
Preferred stock value	125	125	2,500
Common stock value	1,835	832	16,642
Additional paid-in capital	1,460,995	1,261,543	1,243,358
Accumulated deficit	(1,247,796)	(1,222,351)	(1,126,558)
Total stockholders' equity	215,159	40,149	135,942
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 219,259	$ 44,249	$ 140,042

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000	5,000,000
Series A Preferred stock, shares issued	125,000	125,000	2,500,000
Series A Preferred stock, shares outstanding	125,000	125,000	2,500,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	195,000,000	195,000,000	195,000,000
Common stock, shares issued	1,834,510	832,235	16,641,822
Common stock, shares outstanding	1,834,510	832,235	16,641,822

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Revenue
Operating expenses:
Officers' compensation	16,500	18,000	71,000	71,000
Professional fees	7,500	7,500	31,925	28,825
Research and development				11,080
Unauthorized expenses				10,320
Other	1,845	2,002	7,868	4,134
Total operating expenses	25,845	27,502	110,793	125,359
Loss from operations	(25,845)	(27,502)	(110,793)	(125,359)
Other income - net:
Proceeds from sale of subsidiary			25,000
Consulting fees relating to sale of subsidiary			(10,000)
Restitution from former officer	400
Other income-net	400		15,000
Net (Loss)	$ (25,445)	$ (20,699)	$ (95,793)	$ (125,359)
Weighted average number of common shares outstanding - basic and diluted	963,633	832,235	16,641,822	16,641,822
Net loss per common share - basic and diluted	$ (0.03)	$ (0.02)	$ (0.01)	$ (0.01)

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($)	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Jun. 30, 2015	$ 2,500	$ 16,642	$ 1,243,358	$ (1,001,199)	$ 261,301
Balance, shares at Jun. 30, 2015	2,500,000	16,641,822
Net (loss) for the year				(125,359)	(125,359)
Balance at Jun. 30, 2016	$ 2,500	$ 16,642	1,243,358	(1,126,558)	135,942
Balance, shares at Jun. 30, 2016	2,500,000	16,641,822
Net (loss) for the year				(95,793)	(95,793)
Balance at Jun. 30, 2017	$ 2,500	$ 16,642	$ 1,243,358	$ (1,222,351)	40,149
Balance, shares at Jun. 30, 2017	2,500,000	16,641,822
Net (loss) for the year					(25,445)
Balance at Sep. 30, 2017					$ 215,159

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
OPERATING ACTIVITIES
Net Loss	$ (25,445)	$ (20,699)	$ (95,793)	$ (125,359)
Changes in operating assets and liabilities
Prepaid expense	(3,000)		(3,000)
Accounts Payable				(1,900)
Accrued expenses				(3,068)
Due to Related Party				(102)
Cash (used) by operating activities	(28,445)	(27,502)	(98,793)	(130,429)
INVESTING ACTIVITIES
FINANCING ACTIVITIES
Proceeds from sale of Units	200,455
Net cash provided by financing activities	200,455
NET INCREASE (DECREASE) IN CASH			(98,793)	(130,429)
CASH - BEGINNING OF THE PERIOD	41,249	140,042	140,042	270,471
CASH - END OF THE PERIOD	$ 213,259	$ 112,540	41,249	140,042
SUPPLEMENTAL DISCLOSURES:
Interest paid
Income taxes paid

Condensed Interim Financial Sta

Condensed Interim Financial Statements	3 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Interim Financial Statements	NOTE 1 - CONDENSED INTERIM FINANCIAL STATEMENTS The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2017 and for all periods presented have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s June 30, 2017 audited financial statements. The results of operations for the period ended September 30, 2017 are not necessarily indicative of the operating results for the full year. Basis of Presentation In the opinion of management, the accompanying balance sheets and related interim statements of operations and cash flows include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Preparing financial statements requires management to make estimates and assumptions the affect the reported amounts of assets, liabilities, revenue and expenses. Actual results and outcomes may differ from management’s estimates and assumptions. Interim results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with information included in the Form 10-K. Reverse Stock Split Effective October 19, 2017, the Company effected a 1-for-20 reverse stock split of its common stock (which reduced the issued and outstanding shares of common stock from 16,641,822 shares to 832,235 shares) and its Series A Preferred Stock (which reduced the issued and outstanding shares of Series A Preferred Stock from 2,500,000 shares to 125,000 shares). The accompanying financial statements retroactively reflect this reverse stock split.

General Organization and Busine

General Organization and Business	12 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General Organization and Business	NOTE 1 - GENERAL ORGANIZATION AND BUSINESS EnzymeBioSystems (the “Company”) was incorporated under the laws of the state of Nevada on June 26, 2009. The Company was organized to conduct any lawful business. The Company contract manufactures specialty enzymes and enzyme related products. To date, the Company has had no revenues.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Revenue recognition The Company will apply the provisions of ASC 605, Revenue Recognition ("ASC 605"). ASC 605 provides guidance on the recognition, presentation and disclosure of revenue in financial statements. ASC 605 outlines the basic criteria that must be met to recognize revenue and provides guidance for the disclosure of revenue recognition policies. The Company will recognize revenue related to product sales when (i) persuasive evidence of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. For the period from June 26, 2009 (inception) to September 30, 2017, the Company has not recognized any revenues. Recent accounting pronouncements Ce a i acco nti g pronounce en s e bee ss d by t e S d o e ta a se t g rga za io s w i c h a re n t yet e fec ive a d t efo e h ve not ye ee a o e b the Co a . e mpac o t Co any's fi a c a l os o nd e su s of ope ations f om dop t on of ese standar s is not expec e t be a er al .	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Accounting The basis is United States generally accepted accounting principles. Earnings per Share The basic earnings (loss) per common share is calculated by dividing the Company’s net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. The Company has not issued any options or warrants or similar securities since inception. Dividends The Company has not yet adopted any policy regarding payment of dividends. No dividends have been paid during the periods shown. Research and development costs Research and development costs are expensed as incurred. The amounts of costs expensed for the years ended June 30, 2017 and 2016 were $0 and $11,080, respectively. Income Taxes The provision for income taxes is the total of the current taxes payable and the net of the change in the deferred income taxes. Provision is made for the deferred income taxes where differences exist between the period in which transactions affect current taxable income and the period in which they enter into the determination of net income in the financial statements. Year-end The Company has selected June 30 as its year-end. Advertising Advertising is expensed when incurred. There has been no advertising during the periods presented herein. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Revenue recognition The Company applies the provisions of ASC 605, Revenue Recognition (“ASC 605”). ASC 605 provides guidance on the recognition, presentation and disclosure of revenue in financial statements. ASC 605 outlines the basic criteria that must be met to recognize revenue and provides guidance for the disclosure of revenue recognition policies. The Company will recognize revenue related to product sales when (i) persuasive evidence of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. For the period from June 26, 2009 (inception) to June 30, 2017, the Company has not recognized any revenues. Recent accounting pronouncements Ce a i acco nti g pronounce en s e bee ss d by t e S d o e ta a se t g rga za io s w i c h a re n t yet e fec ive a d t efo e h ve not ye ee a o e b the Co a . e mpac o t Co any’s fi a c a l os o nd e su s of ope ations f om dop t on of ese standar s is not expec e t be a er al .

Going Concern

Going Concern	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 - GOING CONCERN These condensed financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of September 30, 2017, the Company has not recognized any revenues and has accumulated operating losses of approximately $(1,247,796) since inception. The Company’s ability to continue as a going concern is contingent upon the successful completion of additional financing arrangements and its ability to achieve and maintain profitable operations. Management plans to raise equity capital to finance the operating and capital requirements of the Company. Amounts raised will be used to further development of the Company’s products, to provide financing for marketing and promotion, to secure property and equipment, and for other working capital purposes. While the Company is putting forth its best efforts to achieve the above plans, there is no assurance that any such activity will generate sufficient funds necessary to continue operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might arise from the outcome of this uncertainty.	NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As shown in the accompanying financial statements, the Company has incurred net losses of $(1,222,351) for the period from June 26, 2009 (inception) to June 30, 2017. The future of the Company is dependent upon its ability to obtain financing and upon future profitable operations from the development of its new business opportunities. Management plans to raise additional capital through private placements and public offerings of its common stock (see Note 8). However, there is no assurance that the Company will raise sufficient capital to implement its business plan. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might arise from the outcome of this uncertainty.

Stockholders' Equity

Stockholders' Equity	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity	NOTE 4 - STOCKHOLDERS' EQUITY The Company is authorized to issue up to 5,000,000 shares of its $0.001 par value preferred stock and up to 195,000,000 shares of its $0.001 par value common stock. The shares of Series A Preferred Stock carry a voting weight equal to 10 shares of common stock per share of Series A Preferred Stock, are not redeemable, and cannot be converted into Common Shares unless it is approved by the Board of Directors and agreed upon by the Series A Preferred Shareholders. The shares of Series A Preferred stock have no dividend rights but have a liquidation preference for funds paid for the Series A Preferred Stock shares. In September, 2017, the Company began conducting a Private Offering, with accredited investors to help fund the Company. The Company is offering up to 3,750,000 Common Units at a price of $0.20 per Unit. Each Unit consists of one share of post reverse stock split common stock, one Class A warrant exercisable at $0.30 per share of post reverse stock split common stock, one Class B warrant exercisable at $0.40 per share of post reverse stock split common stock and one Class C warrant exercisable at $0.60 per share of post reverse stock split common stock. The Offering provides that Berkeley Clinic, L.C. (holder of 75,000 post reverse stock split shares of Common Stock and 125,000 post reverse stock split shares of Series A Preferred Stock) will maintain the same 63.6% voting control of the Company that it held prior to the Offering. The offering and sale of the Units in this Offering are intended to be exempt from registration under the Act by virtue of Section 4(2) of the Act, and Rule 506. From September 6, 2017 to September 30, 2017, we sold a total of 1,002,275 Common Units to 8 investors at a price of $0.20 per Unit for gross proceeds of $200,455. The Class A, Class B, Class C and Class D warrants all expire August 31, 2022, and all provide for the reduction of that exercise price if we directly or indirectly sell or grant any right with respect to our common stock or common stock equivalents at an effective price lower than the current exercise price of any of the Class A warrants.	NOTE 4. STOCKHOLDERS’ EQUITY The Company is authorized to issue up to 5,000,000 shares of its $0.001 par value preferred stock and up to 195,000,000 shares of its $0.001 par value common stock. The shares of Series A Preferred Stock are not redeemable and cannot be converted into Common Shares, unless it is approved by the Board of Directors and agreed upon by the Series A Preferred Shareholders. The shares of Series A Preferred Stock have no dividend rights but have a liquidation preference for funds paid for the Series A Preferred Stock shares. The Series A Preferred Shares carry a voting weight equal to ten (10) Common Shares per share of Series A Preferred Stock.

Other Income - Net

Other Income - Net	12 Months Ended
	Jun. 30, 2017
Other Income and Expenses [Abstract]
Other Income - Net	NOTE 5. OTHER INCOME - NET On March 24, 2017, the Company received $25,000 from Her Imports for the sale of the remaining capital stock of Shareholder Acquisition Corp. (“SAC”), an entity formed by the Company on January 10, 2017, following a dividend spin-off of a total of approximately 24,125 shares of SAC capital stock (1 share of SAC capital stock for each 800 shares of Company common and preferred stock owned) to the Company‘s stockholders of record on January 30, 2017. In connection with the transaction, the Company paid two consultants affiliated with our controlling stockholder Berkeley Clinic, LC a total of $10,000 in March 2017. The Company has reflected other income - net of $15,000 in the accompanying Statement of Operations for the year ended June 30, 2017.

Related Party Transactions

Related Party Transactions	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 5 - RELATED PARTY TRANSACTIONS On September 17, 2017, the Company organized a Nevada corporation named LCNS as a subsidiary of the Company. On September 29, 2017, LCNS sold 2,000,000 restricted shares of LCNS common stock to T. J. Jesky (1,000,000 shares) and Mark DeStefano (1,000,000 shares) at a price of $.005 per share and $10,000 was deposited in LCNS’s attorney’s client trust account. Jesky and DeStefano are members of Berkely Clinic, L.C. (see Note 4). The officers and directors of the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interests. The Company has not formulated a policy for the resolution of such conflicts.	NOTE 6 - RELATED PARTY TRANSACTIONS On September 21, 2015, the Company’s then chief financial officer (appointed October 20, 2014) was dismissed for his alleged payment of unauthorized expenses totaling approximately $36,018 ($25,698 in the year ended June 30, 2015 and $10,320 in the six months ended December 31, 2015). The Company’s officers filed a criminal complaint and on January 26, 2017, the Company’s former chief financial officer entered into a Guilty Plea Agreement, in Nevada District Court, Case Number C-16-319713-1, using an Alford plea to attempted theft. He was ordered to pay restitution to the Company of $25,000 over the next three years. On July 7, 2017 and September 8, 2017 the Company received a total of $400 of the $25,000 ordered restitution. The officers and directors of the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interests. The Company has not formulated a policy for the resolution of such conflicts.

Provision for Income Taxes

Provision for Income Taxes	12 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Provision for Income Taxes	NOTE 7 - PROVISION FOR INCOME TAXES The Company accounts for income taxes under ASC 740, “Accounting for Income Taxes”, which requires use of the liability method. ASC 740 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. Deferred tax assets and liabilities at the end of each period are determined using the currently enacted tax rates applied to taxable income in the periods in which the deferred tax assets and liabilities are expected to be settled or realized. The provision for (benefit from) income taxes differs from the amount computed by applying the statutory federal income tax rate to income (loss) before provision for income taxes. The sources and tax effects of the differences are as follows: Year Ended June 30 2017 2016 Expected tax at 35% $ (33,528 ) $ (43,875 ) Increase in valuation allowance 33,528 43,875 Provision for (benefit from) income taxes $ - $ - Deferred tax assets as of June 30, 2017 and June 30, 2016 are calculated as follows: 2017 2016 Deferred tax assets: Net operating loss carry forward $ 427,823 $ 394,295 Less: valuation allowance (427,823 ) (394,295 ) Net deferred tax assets $ - $ - During the year ended June 30, 2017, the Company recorded an increase in the valuation allowance of $33,528, as compared to $43,875 for the previous year, on the deferred tax assets to reduce the total to an amount that management believes will ultimately be realized. Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carryforwards are expected to be available to reduce taxable income. There was no other activity in the valuation allowance account during the year ended June 30, 2017. The net operating loss carryforward of approximately $1,222,351 at June 30, 2017 expires commencing in year 2029. Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carryforwards for Federal income tax reporting purposes are subject to annual limitations. Should a significant change in ownership occur, net operating loss carryforwards may be limited as to use in the future. The Company has no tax positions. All tax years remain subject to examination by taxing jurisdictions.

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 6 – Subsequent Events Effective October 19, 2017, the Company effected a 1-for-20 reverse stock split of its common stock (which reduced the issued and outstanding shares of common stock from 16,641,822 shares to 832,235 shares) and its Series A Preferred Stock (which reduced the issued and outstanding shares of Series A Preferred Stock from 2,500,000 shares to 125,000 shares). The accompanying financial statements retroactively reflect this reverse stock split. From October 1, 2017 to December 12, 2017, we sold a total of 1,757,500 Common Units (see Note 4) to 8 investors at a price of $0.20 per Unit for gross proceeds of $351,500. In November 2017, the Company paid $99,200 to an investor relations firm for services rendered for the Company. On December 12, 2017, the Board of Directors approved the issuance of 2,000,000 common shares of the Company’s $0.001 par value common stock to Gary Rojewski, the CEO of the Company from June 2, 2014 to December 27, 2017 (when he resigned for personal reasons). Although the stock was issued for past services rendered, Mr. Rojewski elected to purchase this common stock at par value or $2,000. On December 12, 2017, the Board of Directors approved the issuance of 2,000,000 Series A Preferred Shares of the Company’s $0.001 par value to Berkeley Clinic, LC an Arizona Limited Liability Company. Berkeley Clinic elected to purchase this preferred stock at par value or $2,000.	NOTE 8 – SUBSEQUENT EVENTS The Company filed a Definitive Information Statement on September 15, 2017 to announce a 1 for 20 reverse stock split. The reverse stock split is scheduled to take place in October, 2017, based on final approval from FINRA. In September, 2017, the Company began conducting a Private Offering, with accredited investors to help fund the Company. The Company is offering up to 3,750,000 Common Units at a price of $0.20 per Unit. Each Unit consists of one share of post reverse stock split common stock, one Class A warrant exercisable at $0.30 per share of post reverse stock split common stock, one Class B warrant exercisable at $0.40 per share of post reverse stock split common stock and one Class C warrant exercisable at $0.60 per share of post reverse stock split common stock. The Offering provides that Berkeley Clinic, LC (holder of 1,500,000 shares of Common Stock and 2,500,000 shares of Series A Preferred Stock) will maintain the same 63.6% voting control of the Company that it held prior to the Offering. The offering and sale of the Units in this Offering are intended to be exempt from registration under the Act by virtue of Section 4(2) of the Act, and Rule 506. As of the end of September, 2017, the Company has raised approximately $200,000. On September 17, 2017, the Company incorporated LCNS in Nevada as a wholly owned subsidiary to conduct different business operations than the Company.

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting		Basis of Accounting The basis is United States generally accepted accounting principles.
Earnings Per Share		Earnings per Share The basic earnings (loss) per common share is calculated by dividing the Company’s net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. The Company has not issued any options or warrants or similar securities since inception.
Dividends		Dividends The Company has not yet adopted any policy regarding payment of dividends. No dividends have been paid during the periods shown.
Research and Development Costs		Research and development costs Research and development costs are expensed as incurred. The amounts of costs expensed for the years ended June 30, 2017 and 2016 were $0 and $11,080, respectively.
Income Taxes		Income Taxes The provision for income taxes is the total of the current taxes payable and the net of the change in the deferred income taxes. Provision is made for the deferred income taxes where differences exist between the period in which transactions affect current taxable income and the period in which they enter into the determination of net income in the financial statements.
Year-end		Year-end The Company has selected June 30 as its year-end.
Advertising		Advertising Advertising is expensed when incurred. There has been no advertising during the periods presented herein.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition	Revenue recognition The Company will apply the provisions of ASC 605, Revenue Recognition (“ASC 605”). ASC 605 provides guidance on the recognition, presentation and disclosure of revenue in financial statements. ASC 605 outlines the basic criteria that must be met to recognize revenue and provides guidance for the disclosure of revenue recognition policies. The Company will recognize revenue related to product sales when (i) persuasive evidence of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. For the period from June 26, 2009 (inception) to September 30, 2017, the Company has not recognized any revenues.	Revenue recognition The Company applies the provisions of ASC 605, Revenue Recognition (“ASC 605”). ASC 605 provides guidance on the recognition, presentation and disclosure of revenue in financial statements. ASC 605 outlines the basic criteria that must be met to recognize revenue and provides guidance for the disclosure of revenue recognition policies. The Company will recognize revenue related to product sales when (i) persuasive evidence of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. For the period from June 26, 2009 (inception) to June 30, 2017, the Company has not recognized any revenues.
Recent Accounting Pronouncements	Recent accounting pronouncements Certain accounting pronouncements have been issued by the FASB and other standard setting organizations which are not yet effective and therefore have not yet been adopted by the Company. The impact on the Company’s financial position and results of operations from adoption of these standards is not expected to be material.	Recent accounting pronouncements Ce a i acco nti g pronounce en s e bee ss d by t e S d o e ta a se t g rga za io s w i c h a re n t yet e fec ive a d t efo e h ve not ye ee a o e b the Co a . e mpac o t Co any’s fi a c a l os o nd e su s of ope ations f om dop t on of ese standar s is not expec e t be a er al .

Provision for Income Taxes (Tab

Provision for Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) Before Provision for Income Taxes	The sources and tax effects of the differences are as follows: Year Ended June 30 2017 2016 Expected tax at 35% $ (33,528 ) $ (43,875 ) Increase in valuation allowance 33,528 43,875 Provision for (benefit from) income taxes $ - $ -
Schedule of Deferred Tax Assets	Deferred tax assets as of June 30, 2017 and June 30, 2016 are calculated as follows: 2017 2016 Deferred tax assets: Net operating loss carry forward $ 427,823 $ 394,295 Less: valuation allowance (427,823 ) (394,295 ) Net deferred tax assets $ - $ -

Condensed Interim Financial S18

Condensed Interim Financial Statements (Details Narrative) (10Q) - shares	3 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Common stock, shares issued	1,834,510	832,235	16,641,822
Common stock, shares outstanding	1,834,510	832,235	16,641,822
Preferred stock, shares issued	125,000	125,000	2,500,000
Preferred stock, shares outstanding	125,000	125,000	2,500,000
October 19, 2017 [Member]
Reverse stock split	1-for-20 reverse stock split
October 19, 2017 [Member] | Minimum [Member]
Common stock, shares issued	832,235
Common stock, shares outstanding	832,235
October 19, 2017 [Member] | Minimum [Member] | Series A Preferred Stock [Member]
Preferred stock, shares issued	125,000
Preferred stock, shares outstanding	125,000
October 19, 2017 [Member] | Maximum [Member]
Common stock, shares issued	16,641,822
Common stock, shares outstanding	16,641,822
October 19, 2017 [Member] | Maximum [Member] | Series A Preferred Stock [Member]
Preferred stock, shares issued	2,500,000
Preferred stock, shares outstanding	2,500,000

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Accounting Policies [Abstract]
Research and development costs		$ 11,080

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended		96 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net losses	$ (25,445)	$ (20,699)	$ (95,793)	$ (125,359)	$ (1,222,351)
Accumulated deficit	$ (1,247,796)		$ (1,222,351)	$ (1,126,558)	$ (1,222,351)

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) (10Q) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Preferred stock, shares authorized	5,000,000	5,000,000	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	195,000,000	195,000,000	195,000,000	195,000,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Shares issued, price per share	$ 0.20	$ 0.20
Voting control percentage	63.60%	63.60%
Eight investors [Member]
Offering of common stock units	1,002,275
Shares issued, price per share	$ 0.20	$ 0.20
Gross proceeds	$ 200,455
Class A Warrant [Member]
Warrants expiration period		Aug. 31, 2022
Class B Warrant [Member]
Warrants expiration period		Aug. 31, 2022
Class C Warrant [Member]
Warrants expiration period		Aug. 31, 2022
Class D Warrant [Member]
Warrants expiration period		Aug. 31, 2022
Post Reverse Stock Split [Member] | Class A Warrant [Member]
Exercise price of warrants	$ 0.30	$ 0.30
Post Reverse Stock Split [Member] | Class B Warrant [Member]
Exercise price of warrants	0.40	0.40
Post Reverse Stock Split [Member] | Class C Warrant [Member]
Exercise price of warrants	$ 0.60	$ 0.60
Post Reverse Stock Split [Member] | Common Stock [Member]
Offering of common stock units		75,000
Post Reverse Stock Split [Member] | Series A Preferred Stock [Member]
Offering of common stock units		125,000
Maximum [Member]
Offering of common stock units		3,750,000
Series A Preferred Stock [Member]
Preferred shares voting rights		The shares of Series A Preferred Stock carry a voting weight equal to 10 shares of common stock per share of Series A Preferred Stock	The Series A Preferred Shares carry a voting weight equal to ten (10) Common Shares per share of Series A Preferred Stock.

Stockholders' Equity (Details22

Stockholders' Equity (Details Narrative) - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Preferred stock, shares authorized	5,000,000	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	195,000,000	195,000,000	195,000,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Series A Preferred Stock [Member]
Preferred shares voting rights	The shares of Series A Preferred Stock carry a voting weight equal to 10 shares of common stock per share of Series A Preferred Stock	The Series A Preferred Shares carry a voting weight equal to ten (10) Common Shares per share of Series A Preferred Stock.

Other Income - Net (Details Nar

Other Income - Net (Details Narrative) - USD ($)	Mar. 24, 2017	Jan. 10, 2017	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017
Other income-net			$ 400		$ 15,000
Shareholder Acquisition Corp [Member]
Proceeds from related party	$ 25,000
Number of dividend spin-off shares		24,125
Dividend spin-off description		1 share of SAC capital stock for each 800 shares of Company common and preferred stock owned
Berkeley Clinic, LC [Member]
Due to affiliate							$ 10,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) (10Q) - USD ($)	Sep. 29, 2017	Sep. 30, 2017
Shares issued, price per share		$ 0.20
J. Jesky [Member]
Stock issued during period, share, restricted stock award, gross	1,000,000
Mark DeStefano [Member]
Stock issued during period, share, restricted stock award, gross	1,000,000
LCNS [Member]
Stock issued during period, share, restricted stock award, gross	2,000,000
Shares issued, price per share	$ 0.005
Stock issued during period, value, restricted stock award, gross	$ 10,000

Related Party Transactions (D25

Related Party Transactions (Details Narrative) - USD ($)	Sep. 21, 2015	Dec. 31, 2015	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015	Jan. 26, 2017
Unauthorized expenses	$ 36,018	$ 10,320		$ 10,320	$ 25,698
Payment of restitution						$ 25,000
July 7, 2017 and September 8, 2017 [Member]
Ordered restitution received			$ 400

Provision for Income Taxes (Det

Provision for Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Increase in valuation allowance	$ 33,528	$ 43,875
Net operating loss carryforward	$ 1,222,351
Operating loss carryforwards expiration year	expires commencing in year 2029

Provision for Income Taxes - Sc

Provision for Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Expected tax at 35%	$ (33,528)	$ (43,872)
Increase in valuation allowance	33,528	43,875
Provision for (benefit from) income taxes

Provision for Income Taxes - 28

Provision for Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details) (Parenthetical)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Expected tax rate	35.00%	35.00%

Provision for Income Taxes - 29

Provision for Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Net operating loss carry forward	$ 427,823	$ 394,295
Less: valuation allowance	(427,823)	(394,295)
Net deferred tax assets

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) (10Q) - USD ($)	Dec. 12, 2017	Oct. 19, 2017	Sep. 15, 2017	Nov. 30, 2017	Sep. 30, 2017	Sep. 30, 2017	Dec. 12, 2017	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Common stock, shares issued					1,834,510	1,834,510		1,834,510	832,235	16,641,822
Common stock, shares outstanding					1,834,510	1,834,510		1,834,510	832,235	16,641,822
Preferred stock, shares issued					125,000	125,000		125,000	125,000	2,500,000
Preferred stock, shares outstanding					125,000	125,000		125,000	125,000	2,500,000
Shares issued price per share					$ 0.20	$ 0.20		$ 0.20
Common stock, par value					0.001	$ 0.001		0.001	$ 0.001	$ 0.001
Eight investors [Member]
Number of shares issued						1,002,275
Shares issued price per share					$ 0.20	$ 0.20		$ 0.20
Number of shares issued value						$ 200,455
Maximum [Member]
Number of shares issued								3,750,000
Subsequent Event [Member]
Reverse stock split		1 for 20 reverse stock split	1 for 20 reverse stock split
Number of shares issued					3,750,000
Shares issued price per share					$ 0.20	$ 0.20		$ 0.20
Subsequent Event [Member] | Series A Preferred Stock [Member] | Berkeley Clinic, LC [Member]
Number of shares issued	2,000,000
Shares issued price per share	$ 0.001						$ 0.001
Number of shares issued value	$ 2,000
Subsequent Event [Member] | Investor Relations Firm [Member]
Shares issued for services rendered				$ 99,200
Subsequent Event [Member] | Eight investors [Member]
Number of shares issued							1,757,500
Shares issued price per share	$ 0.20						$ 0.20
Number of shares issued value							$ 351,500
Subsequent Event [Member] | Gary Rojewski [Member]
Number of shares issued	2,000,000
Number of shares issued value	$ 2,000
Common stock, par value	$ 0.001						$ 0.001
Subsequent Event [Member] | Minimum [Member]
Common stock, shares issued		832,235
Common stock, shares outstanding		832,235
Subsequent Event [Member] | Minimum [Member] | Series A Preferred Stock [Member]
Preferred stock, shares issued		125,000
Preferred stock, shares outstanding		125,000
Subsequent Event [Member] | Maximum [Member]
Common stock, shares issued		16,641,822
Common stock, shares outstanding		16,641,822
Subsequent Event [Member] | Maximum [Member] | Series A Preferred Stock [Member]
Preferred stock, shares issued		2,500,000
Preferred stock, shares outstanding		2,500,000

Subsequent Events (Details Na31

Subsequent Events (Details Narrative) - USD ($)	Oct. 19, 2017	Sep. 15, 2017	Sep. 30, 2017
Shares issued price per share			$ 0.20
Subsequent Event [Member]
Reverse stock split	1 for 20 reverse stock split	1 for 20 reverse stock split
Number of shares issued			3,750,000
Shares issued price per share			$ 0.20
Proceeds from initial public offering			$ 200,000
Subsequent Event [Member] | Berkeley Clinic, LC [Member]
Voting percentage			63.60%
Subsequent Event [Member] | Berkeley Clinic, LC [Member] | Common Stock [Member]
Number of shares issued			1,500,000
Subsequent Event [Member] | Berkeley Clinic, LC [Member] | Series A Preferred Stock [Member]
Number of shares issued			2,500,000
Subsequent Event [Member] | Class A Warrant [Member]
Warrant exercise price per share			$ 0.30
Subsequent Event [Member] | Class B Warrant [Member]
Warrant exercise price per share			0.40
Subsequent Event [Member] | Class C Warrant [Member]
Warrant exercise price per share			$ 0.60